KRAS-mutated cancers are heterogeneous, and genomic commutations, MET amplification, metabolic reprogramming, and EGFR signaling represent some possible mechanisms of resistance to the KRASG12C inhibitors and immunotherapy [6,25,26,27,28,29]. The gene discussed is KRAS; the disease is cancer.